Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Ilunocitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 known ✓ | O60674 | 19/20 | 0.79 |
| ▸ | JAK1 known ✓ | P23458 | 19/20 | 0.79 |
| ▸ | JAK3 known ✓ | P52333 | 13/20 | 0.79 |
| ▸ | TYK2 known ✓ | P29597 | 1/20 | 0.74 |
| ▸ | CIT | O14578 | 1/20 | 0.74 |
| ▸ | GAK | O14976 | 1/20 | 0.74 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.74 |
| ▸ | ULK1 | O75385 | 1/20 | 0.74 |
| ▸ | PRKCB | P05771 | 1/20 | 0.74 |
| ▸ | RET | P07949 | 1/20 | 0.74 |
| ▸ | PRKCA | P17252 | 1/20 | 0.74 |
| ▸ | PRKACA | P17612 | 1/20 | 0.74 |
| ▸ | MARK3 | P27448 | 1/20 | 0.74 |
| ▸ | STAT3 | P40763 | 1/20 | 0.74 |
| ▸ | CLK1 | P49759 | 1/20 | 0.74 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.74 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.74 |
| ▸ | MAP3K1 | Q13233 | 1/20 | 0.74 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.74 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ilunocitinib SCHEMBL29577031 | 0.96 | JAK2 (0.85) | JAK2JAK1JAK3CITGAK | |
| Ilunocitinib SCHEMBL871352 | 0.91 | JAK2 (0.75) | JAK2JAK1JAK3CITGAK | |
| Baricitinib SCHEMBL871037 | 0.90 | JAK1 (0.92) | JAK2JAK1JAK3CITGAK | |
| SCHEMBL20713850 | 0.89 | JAK2 (0.79) | JAK2JAK1JAK3CITGAK | |
| SCHEMBL24772829 | 0.88 | JAK2 (1.00) | JAK2JAK1JAK3CITGAK | |
| SCHEMBL24772828 | 0.88 | JAK2 (1.00) | JAK2JAK1JAK3CITGAK | |
| SCHEMBL2394666 | 0.88 | JAK2 (1.00) | JAK2JAK1JAK3CITGAK | |
| SCHEMBL22730715 | 0.87 | JAK2 (0.77) | JAK2JAK1JAK3CITGAK | |
| SCHEMBL22730714 | 0.87 | JAK2 (0.77) | JAK2JAK1JAK3CITGAK | |
| SCHEMBL20713836 | 0.87 | JAK2 (0.82) | JAK2JAK1JAK3CITGAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130225556-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2013-08-29 | — | — | US | disclosed |
| US-8420629-B2 | Azetidine and cyclobutane derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2013-04-16 | — | — | US | disclosed |
| US-8158616-B2 | Azetidine and cyclobutane derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2012-04-17 | — | — | US | disclosed |
| US-20120077798-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2012-03-29 | — | — | US | disclosed |
| US-20090233903-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225556-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885JAK3 3/4885 |
| US-20090233903-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885JAK3 3/4885 |
| US-20120077798-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885JAK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.